English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Conclusion A single centre retrospective cohort study of 1,034 cycles (Jan 2012-Jan 2016) at Hammersmith IVF unit, where rFSH (GonalF) alone was used to induce follicular growth. Size of each individual follicle at each ultrasound scan and rFSH doses during COS were collated. Parametric groups were compared by ANOVA with post hoc Tukey’s and non-parametric data by Kruskall Wallis test with post hoc Dunn’s tests. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. During IVF treatment, recombinant FSH (rFSH) is used to induce multi-follicular growth (controlled ovarian stimulation; COS). Insufficient rFSH dose negatively impacts the number of oocytes retrieved, whereas excessive dose risks the potentially life-threatening complication ovarian hyperstimulation syndrome (OHSS). Hence, appropriate rFSH dosing is regarded as a key treatment decision affecting both the success and safety of IVF treatment. Current dosing calculators for rFSH are derived to number of oocytes retrieved, however we investigated whether rFSH dosing can more accurately predict follicular growth.

Recombinant FSH dosing during controlled ovarian stimulation in IVF treatment